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The NHMRC Clinical Trials Centre at the University of Sydney conducts large multicentre 
investigator-initiated clinical trials, takes part in trials of national and international 
collaborative trial groups and contributes expertise to trials run by others.  It also:
•	 takes a lead in proposing new directions for trial research in Australia, particularly with 
regard to integrating clinical trials with national policy and clinical practice
•	 undertakes methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials and is at the forefront of 
developments in methods, such as prospective meta-analysis
•	 advises on trial design and  operation, and randomises patients and analyses data for 
other groups conducting trials
•	 offers postgraduate supervision in all of these areas
•	 offers a postgraduate program in clinical trials research by distance education
•	 runs short courses in the design and conduct of clinical trials as part of its undertaking to 
train people for Australian medical research
Core funding is provided by the NHMRC, and specific projects are funded by government, 
public and private institutions and the pharmaceutical industry. 
The CTC is at two sites in Camperdown in inner Sydney — the Medical Foundation 
Building on Parramatta Road and on Mallett Street.
This report covers the CTC’s achievements for 2010.
IntRoDUCtIon
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DIRECTORS’ REPORT
a routine clinical assessment for patients entering 
clinical trials.
We have advanced in our aim of providing 
evidence for tailoring treatments to individual 
patients. We integrate molecular sciences into clinical 
trials design where possible. Identifying genetic and 
molecular markers can lead to optimising treatment 
for individual patients. One recently published 
exploratory study, using data from several trials 
including CO.17, showed that colorectal tumours with 
mutations at a specific locus might be treatable by 
cetuximab. In cardiovascular disease, blood samples 
from the completed FIELD and LIPID prevention 
trials are the subject of extensive laboratory studies. 
FIELD continues to generate new research questions 
answerable from its large diabetes dataset; in 2010, 
we published important findings on renal disease and 
silent myocardial infarction. 
Many of the CTC’s collaborative projects are 
international prospective meta-analyses. Typically, 
these studies combine data from a CTC trial with 
data from other similar trials for aggregate analysis. 
Neonatal studies, in particular, usually require large 
numbers of patients for valid analysis; recently 
published examples are MAPPiNO and PreVILIG. 
The CTC’s BOOST II trial is part of the international 
NeOProM meta-analysis. Dr Lisa Askie, head of the 
CTC’s systematic reviews and health technology 
assessment group, is a leader in neonatal studies. 
MetaGIST, a meta-analysis of trials of the AGITG 
and international collaborators, revealed important 
results on the optimum therapy for some patients 
with stomach cancers. Cardiovascular meta-analyses 
have recently generated important evidence to 
underpin treatment of patients with acute coronary 
syndromes; examples are Primary Coronary 
Angioplasty versus Thrombolysis-2 and the HERO-2 
study of international differences. The Cholesterol 
Treatment Trialists’ Collaboration analysed data 
from 170 000 patients to show that the greater the 
lowering of LDL cholesterol at any level the greater 
the reductions in cardiovascular risk.
The CTC is at the forefront of research into clinical 
trials methodology. Much of this work is being done 
by the CTC’s biostatisticians, led by Professor Val 
The CTC continues to provide intellectual leadership, 
evidence from trials-related research, and operational 
expertise in clinical trials to improve clinical practice 
and health outcomes in Australia and elsewhere. 
In 2010, we made many important steps toward 
improving health through trials research. We 
continue to work in partnership and collaboration 
with many Australian and international investigators, 
without whom these and other major advances 
would not be possible. 
A theme of this year’s report is to highlight some 
of the important work of early-career investigators, 
who are future research leaders at the CTC and 
elsewhere. We trust that others will be as impressed 
as we are by their achievements and ideas.
Our oncology group, managed by Burcu Vachan, 
has grown to over 40 staff working with 7 national 
collaborative groups and currently undertaking 35 
projects. Trials now cover almost all cancer disease 
areas, corresponding to our aim to conduct research 
in areas of need in Australia. The results of MAX, 
initiated by the Australasian Gastro-Intestinal Trials 
Group (AGITG) in partnership with the CTC, showed 
significant improvements in progression-free survival 
with newer combination therapy. Further analyses 
will cover genetic studies of tumour tissue and quality 
of life. Other concluded gastrointestinal studies 
in 2010 include ATTAX, a trial of treatment for 
oesophagogastric cancer, and the biliary tract study. 
Testicular cancer is largely curable, and the current 
optimum treatment has been defined by the 2010 
results of the BEP germ-cell trial conducted by the 
CTC and the Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP). With 
the Sydney Cancer Centre, we conducted the first 
randomised trial comparing inpatient and outpatient 
administration of chemotherapy, which showed 
that outpatient treatment was preferred by most 
patients, appeared safe, and reduced the strain on 
hospital systems. Research into patients’ preferences 
and quality of life are continuing as an important 
strand of oncology research: a breast cancer study 
concluded that wellbeing was related to response 
to chemotherapy and that quality of life should be 
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Gebski. A recent study developed models to predict 
the rates of intramammary lymph node metastasis in 
breast cancer. Another breast cancer study provided 
evidence that historical cross-trial and other non-
randomised comparisons have limited validity and 
confirmed the importance of randomised trials. 
In cardiovascular disease, data from the LIPID trial 
were used to develop a method to analyse recurrent 
events, and data from FIELD to devise a method for 
adjusting the size of the effect of the study drug for 
changes in background treatment in long-term trials. 
As part of the CTC’s technology assessment research, 
a new clinical sign was evaluated — the nerve root 
sedimentation sign — which appears to be useful in 
clinical practice to distinguish lumbar spinal stenosis 
from low back pain from other causes.
A new health economics team has been 
established at the CTC, led by Professor Deborah 
Schofield. This group is implementing aspects of our 
continuing policy to incorporate measures of benefit, 
harm and cost into trials. They are also improving 
methods for analysing cost-effectiveness and cost-
utility in trials and have published a series of studies 
on the financial effects of chronic illness.
In 2010, we developed a new postgraduate course 
in clinical research, which starts enrolment in the 
first semester of 2011. The new course complements 
our long-running program of seminars and short 
courses as well as our in-house supervision of 
research students. The process was helped by 
our earlier experience in the groundwork of the 
successful biostatistics postgraduate program of the 
Biostatistics Collaboration of Australia.
In summary, our research program is focused 
on addressing research questions relevant to 
improving clinical practice and health outcomes in 
major disease areas. We have continued to work 
with collaborative trial groups, helped build new 
networks and groups in areas of need, and added 
value to the results of trials through substudies and 
methodological research. The skill and experience of 
our research teams and collaborators in biostatistics, 
clinical research design and trial conduct, clinical 
epidemiology, and health economics, and the 
dedication of CTC staff have been essential to our 
success.
CTC executive
CTC operations and research are led by the Executive: John 
Simes, director; Tony Keech, deputy director; Wendy Hague, 
trials program director; and Kim Russell-Cooper, general 
manager.
Professor John simes is the foundation director of the CTC 
and represents the CTC on many national and international 
committees. In 2010 he received the 2010 Medical Oncology 
Group of Australia Award to recognise an outstanding 
contribution to medical oncology in Australia through the 
scientific study of cancer. 
Professor Anthony Keech is Professor of Medicine, 
Cardiology and Epidemiology at the University of Sydney.  
He is chairman of the international FIELD study on heart 
disease and diabetes and directs the CTC’s research program.
Dr Wendy Hague is primarily responsible for the successful 
conduct of the CTC’s large-scale, multicentre clinical trials 
and ensuring that trials systems, procedures and methods 
are of the highest standard. 
Kim Russell-Cooper works with the CTC executive, 
managers and research staff toimprove the business 
process in the areas of clinical trial research governance, 
risk assessment, financial planning, management and 
reporting.
John simes Anthony Keech
Wendy Hague Kim Russell-Cooper
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TEACHING CLINICAL TRIALS
New qualification is a foundation for a career in clinical research
MAsteRs In CLInICAL tRIALs
A major achievement of the CTC in 2010 is the 
launching of a new postgraduate course in clinical 
trials research at the University of Sydney, which is 
enrolling students from the first semester of 2011. It 
is for doctors, researchers, consultants, health care 
professionals, data managers and nurse practitioners 
who are working in or planning to pursue 
opportunities in clinical research.
The course will equip graduates with the skills to 
design and lead clinical trials, including specifically:
•	 developing trial concepts
•	 choosing optimal trial designs
•	 leading protocol development
•	 implementing trial protocols
•	 developing operational strategies for trial conduct
•	 collecting and critically analysing trial data
•	 presenting, reporting and interpreting trial results
•	 evaluating trial designs and methods
•	 leading systematic reviews and meta-analyses
•	 identifying funding options
•	 assessing patient outcomes
•	 identifying and interpreting issues related to 
health economic outcomes
In summary, the course will provide a solid 
understanding of research methods, clinical trials 
literature, and the clinical trials process (such as 
trial design, scheduling of interventions, doses of 
treatment, and statistical and ethical considerations).
Teaching is by distance education. The course is 
offered part-time, with the options of pursuing a 
graduate certificate, graduate diploma or masters 
degree, or studying individual units for interest or 
professional development.
Teaching Clinical Trials
Opportunities to learn about clinical trials  
from the experts
Courses over one to five days provide opportunities for people 
wanting to learn about specific aspects of clinical trials. 
In 2010 the CTC presented its introductory course for new 
clinical trials staff: ‘Introduction to clinical trials’, which has two 
2-day modules, one on methods and design and one on trial 
management. Participants learned from CTC presenters with 
experience and state-of-the-art knowledge in the development 
and management of trials, trial design and statistical analysis. 
Concept development workshops for people pursuing 
clinical research were run at intervals over the year. This one-day 
workshop helps investigators to develop existing concepts for 
new trials. It covers objectives, population, interventions, study 
design, outcome measures, sample size, the analysis plan and 
funding strategies. Participants work on their proposed concepts 
throughout the day and present them for discussion in small-
group sessions supported by faculty experts.
CTC shares knowledge for research  
into Aboriginal health
The CTC and Menzies School of Health Research have begun 
a long-term research collaboration. Menzies has a national 
reputation in conducting important Indigenous health research 
and understands the special health needs and culturally 
appropriate methods for research involving Indigenous 
populations. Menzies conducts trials in respiratory disease, 
kidney disease and paediatric disorders. 
CTC biostatisticians and trials staff are lending their skills 
and knowledge in trials management and aspects of design and 
methods, including randomising patients, sources of patients, 
sample size, and measuring outcomes. 
This emerging collaboration will allow the CTC to broaden 
its clinical trials expertise in the methodologically challenging 
area of Aboriginal health and 
is expected to lead to future 
joint public health research 
initiatives.
Biostatistics Collaboration 
of Australia
After 10 years, the BCA is now well established 
as a postgraduate coursework program 
delivered by distance education, serving the 
need for qualified biostatisticians in Australia 
and elsewhere. The BCA has an annual 
enrolment of around 250 students. The CTC 
was a key contributor in the establishment of 
the BCA, which is administered from the CTC.
www.bca.edu.au
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EVIDENCE FOR CLINICAL DECISION MAKING AND POLICY
Professor Deborah schofield, pictured above.
Health economics
Health economics researchers at the CTC, led by 
Professor Deborah Schofield, and their collaborators, 
have undertaken a series of studies on cost-effective-
ness and the economic impacts of illness. 
Cost-eFFeCtIVeness stUDIes
The health economics team work closely with 
clinicians in fields including oncology, neonatal 
care and cardiovascular disease in evaluating cost-
effectiveness of medical interventions. In one such 
study, a Markov model has been developed to assess 
the long-term effectiveness and cost-effectiveness of 
the sentinel node biopsy procedure in women with 
early breast cancer. The model provides estimates of 
cost and effectiveness of the treatment over a 20-
year period, and is able to identify priorities for future 
research in this area.
eConoMIC BURDen oF ILLness
The health economics team and partners at the 
university of Canberra (NATSEM) have developed a 
microsimulation model used for a series of studies 
which generates information on employment, 
income, social security, taxation and poverty called 
Health&WealthMOD, 
Diabetes and cardiovascular disease, both research 
priorities of the CTC, are important causes of early 
retirement. In an investigation of the financial 
vulnerability of people with diabetes, it was found 
that those retiring from the labour force early 
because of diabetes had significantly less wealth and 
90% less chance of accumulating wealth than others. 
People with cardiovascular disease were in a similarly 
difficult situation: nearly 20% of those who retired 
early had no income-producing assets. 
Another study, published in the 
British Journal of Psychiatry, quantified 
the lost savings and lesser wealth of 
people who retire early because of 
depression or other mental illness. 
People who retired early because of 
mental illness had 93% less accumulated 
wealth than people who continued 
to work. Preventing common chronic 
diseases and increasing workforce 
participation would help many people to 
self-finance the costs of retirement and 
ageing.
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Evidence for clinical decision making and policy
EVIDENCE FOR CLINICAL DECISION MAKING AND POLICY
Costs oF PReMAtURe MoRtALItY In AUstRALIA
Decisions to publicly fund effective health interventions in Australia 
are generally based on costs that occur in the health sector alone. 
But premature mortality also reduces household income, savings 
and superannuation, tax revenue and economic productivity. This 
research will highlight the costs to individuals and society as a whole, 
which may have significant implications for how decision makers 
choose to allocate scarce resources.
Hannah Verry hopes her work will provide a valid method of 
incorporating societal costs into economic evaluations of health 
interventions and also that it will signal the economic benefits of 
disease prevention.
‘I wanted to be able to 
combine my background 
in pure economics with 
my current work in health 
research, in particular 
clinical trials. My research 
topic allows me to make 
use of both these sets of 
skills and experience’, 
Hannah says.
Left:  
Health economics researchers: 
Deborah schofield, Hannah Verry 
and emily Callendar.
Hannah Verry
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negative sedimentation sign
Normal nerve root sedimentation
Positive sedimentation sign
Nerve root sedimentation absent
normally, nerve roots fall towards the back 
in a patient lying supine because of gravity.
In patients with stenosis, the roots do 
not move. A positive sedimentation sign 
indicates no gravitational movement.
Clinical validity of diagnostic tests
symposium 
panellists:  
Alex Barratt,  
John simes,  
Les Irwig 
(obscured);  
Paul Glasziou, 
tracy Merlin, 
Frederick Khafagi, 
Andrew Mitchell,  
George 
Koumantakis
A strand of the CTC’s research is evaluation of new 
tests and technology to obtain evidence of their value 
in clinical decision making and policy.
In a study published in Spine in 2010, PhD student 
Lukas Staub, epidemiologist Sally Lord and their 
colleagues addressed the difficulty of distinguishing 
lumbar spinal stenosis, which can be treated by 
surgery, from low back pain from other causes. 
Magnetic resonance imaging with the patient lying 
down had shown that without spinal stenosis, the 
nerve roots move toward the back because of gravity. 
In patients with stenosis, the nerve roots do not 
move. This was termed the ‘sedimentation sign’. The 
performance of this sign was tested in a large group 
of patients; it was 100% successful in excluding spinal 
stenosis, but slightly less successful in identifying it. 
The study has provoked further research in this area: 
Is the sedimentation sign applicable to a broader 
range of patients? Can this sign identify patients 
who will benefit from surgery? Is it related to clinical 
symptoms?
Gr
av
ity
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Evidence for clinical decision making and policy
MetHoDs FoR eVALUAtInG neW tests
Dr Lukas staub, with epidemiologist Sally Lord, is developing 
new methods of clinical test evaluation. He previously worked in 
orthopaedic research at the MEM Research Center, University of Bern, 
Switzerland, but realised that his main interest lay in clinical trials 
methodology.
His PhD project is about bridging the gap between two broad 
research domains—studies of diagnostic test accuracy and clinical 
trials of treatment effectiveness. 
Demonstrating how new tests affect treatment selection and 
subsequent outcomes will lead to both better health of patients 
and more efficient use of health expenditures. He hopes that, after 
completing his PhD, he will continue to develop and publish these 
ideas in order to improve the evidence base on which clinicians make 
decisions about the use of medical tests in everyday practice. 
Lukas says: ‘The main driver for moving to Sydney was the 
CTC’s international reputation, although other factors, such as 
my wife’s career, were important for this decision too. It is a very 
satisfying experience to work at the CTC. I’m allowed to work with 
the top experts in my field, in a highly motivating and supportive 
environment’.
‘The main driver 
for moving to 
Sydney was the 
CTC’s international 
reputation. I’m 
allowed to work 
with the top experts 
in my field, in a 
highly motivating 
and supportive 
environment.’
Symposium on test evaluation
The Test Evaluation Symposium at the University of Sydney in 
September 2010, attended by 70 people, had an agenda of the 
frameworks, criteria and evidence requirements for assessing the 
clinical effectiveness and economic impact of medical tests. 
It was organised by the CTC’s Systematic Reviews and Health 
Care Assessment group with support from the Screening and Test 
Evaluation Program at the School of Public Health. Speakers, including 
clinicians, researchers and government decision makers, represented a 
wide range of views.
Dr Lukas staub
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Translational research is the application of 
laboratory discoveries to improvements in 
treatment and care of patients. The CTC and its 
collaborative groups aim to build translational 
research into trials as far as possible. 
Currently, most trials the CTC coordinates 
include an option for patients to consent to 
biological samples being used in research or 
being banked for future research. 
Typically, samples of blood or tumour tissue 
are collected, then analysed in the laboratory. 
Individual biomarkers that correlate with 
a patient’s clinical outcomes may forecast 
survival or predict the response of a patient 
to a particular treatment. Sometimes genetic 
testing is done before selecting patients for a 
trial because the treatment is already known to 
benefit some patients and not others, depending 
on their genetic profile.
tRAnsLAtIonAL ReseARCH:  
BenCH to BeDsIDe
Tailoring the treatment to an 
individual patient
Clinical trials have traditionally determined the 
effectiveness of treatments in large samples of 
patients. Modern researchers attempt to build 
on trial results to elucidate the best treatment 
for individual patients. Individual responses to 
treatment depend on various factors, including 
genes, quality of life, psychological factors, lifestyle, 
and the level of risk of the disease or disorder. At the 
CTC, this research has three strands: first, detecting 
genetic and molecular markers in tumour tissues or 
blood that may modulate the effect of a treatment 
(that is, translational research); second, determining 
individual risk where a treatment is more effective 
for patients at high risk; and third, identifying the 
characteristics of the patient that may correlate 
with benefit of treatment, such as quality of life and 
psychological factors. 
An example is a study published in the British 
Journal of Cancer, in which Chee Lee and colleagues 
sought to identify patients in three breast cancer 
trials who were more or less likely to respond 
to chemotherapy on the basis of their reported 
quality of life. The results showed the value of using 
quality-adjusted outcomes in trials and revealed 
a need for trials of new treatment approaches for 
women with poor quality of life. Current work 
includes developing a prognostic nomogram to 
predict overall survival by using available clinical 
and laboratory data and identifying individual gene 
expression that predicts sensitivity or resistance to 
treatment for colorectal cancer.
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tRAnsLAtIonAL ReseARCH In onCoLoGY: 
LABoRAtoRY stUDIes HeLP to MAtCH 
tReAtMent to PAtIents
A previous genetic study of patients from one of 
the CTC’s collaborative trials, CO.17, showed that 
treatment with a monoclonal antibody, cetuximab, 
improved survival only in colorectal cancer patients 
whose tumours had the KRAS wild-type gene, 
not the mutated gene. A collaboration of the 
National Cancer Institute of Canada (NCIC) and the 
Australasian Gastro-Intestinal Trials Group (AGITG) 
recently re-examined the KRAS genetic marker in 
tumour tissue from over 500 patients in this and 
similar trials.
The results, published in JAMA in 2010, showed 
that even within the group of patients with KRAS 
mutations, cetuximab prolongs the survival of 
patients with the specific KRAS p.G13D mutation, 
but not those with other kinds of KRAS mutations. 
They observed the same responses of the mutated 
tumours to the drug in laboratory studies in cell lines, 
and now the overall result remains to be confirmed in 
prospective clinical trials.
Another study, MetaGIST, was an international 
meta-analysis of data from Australia, Europe and the 
United States, which showed that gastrointestinal 
stromal tumour patients with a particular mutation 
(KIT exon 9) have delayed disease recurrence with 
high-dose imatinib treatment (p. 14).
survival in patients with advanced colorectal cancer in 
different KRAs genetic groups, from a collaborative study 
using data from Co.17 and other similar trials.
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Prospective meta-analysis of trial data
MetA-AnALYsIs oF DAtA FRoM  
neonAtAL VentILAtIon tRIALs
The PreVILIG (Prevention of Ventilator Induced Lung 
Injury Collaborative Study) Group recently published 
a systematic review and meta-analysis of data from 
10 trials comparing controversial high-frequency 
oscillatory ventilation (HFOV) and conventional 
ventilation for preterm infants, finding that HFOV 
appeared just as effective as conventional ventilation. 
This meta-analysis was a collaborative effort 
involving investigators from the original trials, who 
worked together to plan the analysis and interpret 
the results. Use of individual patient’s data improved 
the assessment of the treatment effect because 
outcomes with varied definitions could be redefined. 
The large number of participants (3229) meant that 
subgroup characteristics, such as gestational age and 
the extent of lung disease, could be analysed as well.
Neonatal and paediatric studies typically 
require large cohorts of patients to show subtle 
effects, so meta-analyses of data from similar 
trials are becoming common. The CTC is leading 
or participating in several such studies: NeOProM 
(Neonatal Oxygenation Prospective Meta-Analysis), 
EPOCH (Early Prevention of Obesity in Children), 
MAPPiNO (Nitric Oxide in Assisted Ventilation) and 
PARIS (Antiplatelets for Preventing Pre-Eclampsia). 
ACUte MYoCARDIAL InFARCtIon
The CTC is part of the Primary Coronary Angioplasty 
versus Thrombolysis-2 Trialists Collaborators group, 
which has conducted a series of meta-analyses of 
trials comparing percutaneous procedures (such as 
insertion of stents and balloons) with drug treatment 
for restoring blood flow in coronary arteries in 
patients with acute myocardial infarction. These 
have shown that percutanous procedures are better 
for patients at high risk, but they are often withheld 
from older patients because of uncertainty about 
the harms and benefits of treatment in this group. 
COMBINING EVIDENCE
Dr Lisa Aslie, director of systematic reviews and  
a leader in meta-analyses in neonatal disorders
MetaGIst: HIGHeR oR LoWeR DosAGe FoR 
GAstRoIntestInAL stRoMAL tUMoURs?
Gastrointestinal stromal tumours are relatively 
common stomach cancers. A proven treatment is 
imatinib, which targets mutated genes in the tumour. 
A trial by the Australasian Gastro-Intestinal Trials 
Group and its European collaborators had shown that 
over the short term, about 2 years, imatinib twice a 
day prevented disease recurrence more effectively 
than the standard daily treatment. However, this 
difference was not sustained over a longer period, 
leading to uncertainty about the best treatment 
regimen. The results of this trial were combined with 
results from an American trial in a meta-analysis 
based on 1640 patients. This confirmed that the 
higher dose did not prolong survival or have any 
advantage for most patients. These results may guide 
clinicians in choosing the best treatment regimen for 
patients with this disease. 
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A recent study pooling data from 22 trials found 
that, for elderly patients well enough to be selected 
for clinical trials, the advantage of percutaneous 
procedures after myocardial infarction was similar 
in older and younger patients. Therefore,  
age is not a reason to exclude patients from the 
better treatment.
InteRnAtIonAL CHoLesteRoL-LoWeRInG 
CoLLABoRAtIon
The Cholesterol Treatment Trialists’ Collaboration 
is one of the largest international prospective 
meta-analysis groups. It was established in 1994 
to analyse data from all relevant large-scale 
randomised trials of cholesterol-lowering therapy, 
so that data from similar trials could be combined 
to study specific outcomes and subgroups of 
patients. The LIPID trial (Long-Term Intervention 
Reviews of evidence in the Cochrane Library
The CTC is the editorial base of the Cochrane Breast Cancer Group, an 
international team of volunteers who prepare, maintain and update 
Cochrane reviews on breast cancer. The CTC staff who form the editorial 
base coordinate these activities and maintain a specialised register of 
breast cancer research references.
sPeCIAL CoLLeCtIon FoR tHe LIBRARY
During October 2010, to coincide with Breast Cancer Awareness Month, 
the Cochrane Breast Cancer Group, with the Cochrane Editorial Unit 
in the UK, prepared a special edition on metastatic breast cancer. 
The collection features 18 Cochrane reviews and focuses on the 
range of treatments available for metastatic breast cancer, including 
chemotherapy, endocrine therapy, psychosocial interventions and 
supportive care. The special edition can be found at: 
http://www.thecochranelibrary.com/details/collection/857471/
Metastatic-Breast-Cancer.html
Melina Willson, project manager, 
Cochrane Breast Cancer Group
with Pravastatin in Ischaemic Disease), coordinated 
by the CTC since 1990, contributes data from 9014 
Australian and New Zealand patients.
The second cycle of planned analyses incorporated 
more trials and has involved nearly 170 000 patients 
from 26 trials (published in 2010 in The Lancet). The 
study analysed data from individual patients to assess 
the effect and safety of reducing LDL cholesterol to 
very low concentrations. Intensive statin therapy 
reduced the vascular risk, even for patients with 
initially very low LDL cholesterol, without cancer risk. 
The investigators recommended that for people at 
high risk of vascular disease, LDL cholesterol should 
be reduced as far as possible, preferably with modern 
statins or with combinations of statins and other 
drugs.
The CTC and the Clinical Trial Service Unit at 
Oxford University coordinate the collaboration.
Australian New Zealand Clinical Trials Registry 
The Australian New Zealand Clinical Trials Registry (ANZCTR) since 2005 has been providing public data on 
clinical trials conducted in Australia, New Zealand and neighbouring regions. It is a primary registry in the 
World Health Organization’s registry network.
New trials submitted for registration averaged 102 per month in 2010—an increase from the 2009 
average of 90 per month. The total number of registered studies has now reached 4772.
AUstRALIAn CAnCeR tRIALs WeBsIte LAUnCHeD In noVeMBeR 2010
Staff of the ANZCTR have been working with others on Australian Cancer Trials, a consumer-friendly website 
providing information about cancer trials in Australia. The University of Sydney, Cancer Australia, Cancer 
Voices and other consumer groups and the CTC collaborated in this project. The site was officially launched 
on 11 November during the COSA Annual Scientific Meeting. Website data are sourced from the ANZCTR 
and clinicaltrials.gov in the United States.
www.australiancancertrials.gov.au
www.clinicaltrials.govwww.anzctr.org.au
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eVIDenCe In A UnIVeRsAL HeALtH CARe sYsteM
Henry Ko, project officer for systematic reviews at the CTC, was one of 30 finalists in an international 
essay competition for young researchers by the Global Forum for Health Research and The Lancet.
His essay ‘Fostering better shared decision-making in universal health coverage in the face of hype, 
hope, and evidence’ argued for the need for and methods to provide evidence-based decision-making 
when it comes to medical therapies in a universal health care system.
Health systems research is rapidly emerging as one of the most dynamic and complex areas of 
research for health. The finalists’ essays are anthologised at http://www.globalforumhealth.org.
 
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Neonatal trials
INIS: study of immunoglobulin  
to prevent disability after  
neonatal infection
2010 was a big year for the International Neonatal 
Immunotherapy Study (INIS). The first patient was 
enrolled in February 2002. Nine years and 1398 
Australian recruits later, the data for 2 years of follow-
up were sent to the National Perinatal Epidemiology 
Unit at Oxford University for amalgamation with data 
from other countries. Australian and New Zealand 
study sites were closed. The results will be published 
in 2011.
APTS: cord blood  
for premature babies
The benefit to a newborn premature infant of 
promoting blood flow from the placenta just after 
birth is unclear. The Australian Placental Transfusion 
Study completed a pilot study of delayed cord 
clamping and cord milking in 2010, and the protocol 
for the main study was finalised. The main study will 
start initially in 10 tertiary centres in Australia.
BOOST II: a major advance in therapy  
for very premature babies
For over 50 years, the best level of oxygenation for 
maximising survival without disability in infants 
born at under 28 weeks’ gestation has remained 
unknown. The accepted range of oxygen saturation 
has varied from 85% to 95%.
BOOST II is a trial comparing disability-free 
survival at 2 years in 1135 infants randomly assigned 
to low (85–89%) or high (91–95%) oxygen 
saturation targets. BOOST II is also part of the 
Australian-led international NeOProM Collaboration, 
a pooled meta-analysis of several trials comprising 
4959 infants. 
In mid-2010, the United States trial, which 
recruited 1316 infants, reported marginally better 
short-term survival with the high target range.
The local data monitoring committee reviewed 
outcomes for 1352 infants in the Australian 
and New Zealand trials and found no reason to 
discontinue recruitment. However, joint analysis of 
the Australasian, United Kingdom and United States 
trials confirmed better survival on the high target, by 
21% in all 3631 infants and by 65% in a prespecified 
group of 1055 infants enrolled after oximeters were 
upgraded with new software. With such definitive 
interim results, BOOST II closed to recruitment in 
December 2010. A report will be published in 2011. 
BOOST II is continuing in follow-up of patients 
and analysis of results.
A BETTER FUTURE FOR NEWBORNS
Lucille sebastian, 
InIs manager
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METHODOLOGY
CTC devises new methods within trials research
cardiovascular process.The analysis also showed 
that the study drug, pravastatin, prevented first and 
second cardiovasacular events to a similar degree. 
A MetHoD to ADJUst FoR DIFFeRentIAL 
BACKGRoUnD tReAtMents In  
LonG-teRM tRIALs
An advance in trial methodology arose from 
difficulties in the statistical analysis of the FIELD 
diabetes trial (p. 26). In this large international trial, 
9795 patients were randomly assigned to fenofibrate 
or placebo and followed up for an average of 5 years. 
Cardiovascular outcomes were measured.
Over the 5 years of the trial, many patients started 
taking newly approved cholesterol-lowering drugs, 
confounding the effect of the study drug. FIELD 
investigators and CTC statisticians devised a novel 
method using the results of other clinical trials to 
adjust the estimates of efficacy of the study drug 
—a method with potential for wide application in 
long-term trials.
A MoDeL to PReDICt RIsK oF ReCURRent 
eVents In tHe LIPID CARDIoVAsCULAR tRIAL
Traditional methods for analysing clinical and 
epidemiological data have focused on the first 
occurrence of the outcome or event being measured. 
These methods can be unsuitable for analysing 
recurring events because a first event may signal 
another one; that is, recurrent events are not 
independent of each other. 
A recent methodological study used the dataset of 
the CTC’s multicentre trial, LIPID, which had shown 
that lipid-lowering with a statin prevented a coronary 
event, such as a heart attack. The LIPID study is still 
following up patients, many years after the main trial 
closed (p.26).
The new study focused on recurring events and 
risk factors and and whether the risk factors were 
different for first and recurrent events. Several 
potentially useful statistical models were applied to 
the data. A semiparametric proportional-hazards 
model and a parametric conditional model were both 
found to be useful tools for exploring the biological 
Adrienne Kirby 
and Kristy Mann, 
biostatisticians
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MoDeLs to PReDICt BReAst CAnCeR  
MetAstAsIs to InteRnAL MAMMARY noDes
An important prognostic factor in breast cancer is the status of 
the internal mammary lymph nodes, that is, whether there is 
tumour in the nodes near the middle of the chest. These nodes 
are less accessible than axillary lymph nodes and less likely to 
be visualised with radio-isotope mapping or to be biopsied. 
Models to predict metastasis in these lymph nodes have been 
developed on the basis of anatomy and tumour biology. These 
will assist cancer clinicians to make decisions about treatment 
when the status of these lymph nodes is not known.
Val Gebski, director, Biostatistics
Clinical Trials Development Unit, an Australian collaboration for  
cancer trial infrastructure
The Clinical Trials Development Unit (CTDU) harnesses the experience and expertise of the CTC  and 
the Centre for Biostatistics and Clinical Trials,  Peter MacCallum Cancer Centre, in Melbourne. The CTDU 
has been supported since 2008 by Cancer Australia. It is an important formal structure for sharing 
information, ideas and resources, thereby adding value to what could be provided by each institution in 
isolation.
The unit provides expert advice and trial development services for recently established cancer 
trials groups, including the Cooperative Trials Group for Neuro-Oncology (COGNO), the Primary Care 
Collaborative Cancer Clinical Trials Group (PC4) and the Australasian Sarcoma Study Group (ASSG).  
The CTDU’s activities include:
•	 expert design of trials, and biostatistical and operational advice for new trials
•	 developing  research grant applications and preparation and management of budgets and finances
•	 advice on case report forms and design of databases for various trials
•	 standard operating procedures, forms and processes to initiate and conduct cancer trials
•	 procedures for quality assurance, particularly in relation to data quality
•	 contributions to collaborative group executive and scientific committees.
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QUALITY OF LIFE AND SURVIVAL IN CANCER
The CTC’s oncology story: a 
better life for cancer patients
It has been nearly 25 years since the CTC began its 
first oncology trial, a randomised comparative study 
of surgery versus radiotherapy and chemotherapy 
in patients with squamous cell carcinoma of the 
head and neck. Much has changed in the world 
of clinical trials since then. The early trials were 
straightforward head-to-head comparisons, with 
simple randomisation to one treatment or the other. 
Now, trials are multidisciplinary studies of surgery, 
chemoradiation and a targeted biological agent (or 
two), sometimes a second randomisation when 
the patient’s disease progresses, and usually value-
added translational substudies (tissue and blood 
collection) and substudies on quality of life, health 
economics and patient preferences. Eighty trials and 
5 collaborative groups coordinated through the CTC 
have recruited nearly 20 000 patients. 
Much of this success is owed to staff at the CTC 
and at the trial sites—the principal investigators, 
nurses, data managers, pharmacists, radiologists and 
others—who have contributed to the research for 
patients and their families living with cancer.
Burcu Vachan, oncology program manager
MAX: tReAtMent FoR ADVAnCeD 
CoLoReCtAL CAnCeR
MAX was an investigation comparing 
capecitabine chemotherapy alone with 
capecitabine plus a genetically engineered 
monoclonal antibody, bevacizumab (with or 
without mitomycin), for patients with advanced 
colorectal cancer, particularly older patients. 
Bevacizumab blocks the growth of the tumour’s 
blood supply. Patients in the bevacizumab 
arms of the trial survived without recurrence on 
average about 8.5 months, or 3 months longer 
than without this treatment. Further analyses of 
the trial data are continuing, and will cover the 
cost-effectiveness of this treatment regimen in 
the Australian health setting, genetic studies of 
tumour tissue, and patients’ quality of life
MAX was initiated and sponsored by the 
Australasian Gastro-Intestinal Trials Group 
(AGITG). Results were published in the Journal of 
Clinical Oncology.
It is therefore heartening to see that in the 
Tebbutt study the addition of bevacizumab 
to single-agent oral fluoropyrimidine 
(capecitabine) … does indeed improve  
PFS and suggests that this combination is 
a reasonable alternative for patients who 
cannot tolerate … the augmented toxic 
effects of dual-agent chemotherapy.
—Yanagisawa and Midgley, 
Nature Reviews: Clinical Oncology, October 2010
‘
‘
HIGHLIGHts oF onCoLoGY  
ReseARCH FoR 2010
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testInG neW tReAtMent FoR 
oesoPHAGoGAstRIC CAnCeR
The phase II trial, ATTAX, evaluated two new 
regimens for oesophagogastric cancer, adding 
docetaxel to either the standard therapy (cisplatin 
and fluorouracil) or to capecitabine. Both regimens 
appeared promising and showed that weekly 
docetaxel regimens are feasible. This AGITG-
sponsored trial appeared in the British Journal  
of Cancer.
oVARIAn CAnCeR
The standard treatment for women with advanced 
ovarian cancer has been chemotherapy with 
paclitaxel and carboplatin, but patients having a 
second round of this treatment after relapse may 
be troubled by cumulative side-effects. CALYPSO 
compared a newer drug, pegylated liposomal 
doxorubicin (with carboplatin) with the standard 
therapy. This combination was not only as good 
as, but better than, the standard treatment in 
prolonging progression-free survival. The new 
treatment is a more effective, less toxic alternative for 
these patients. The report appeared in the  
Journal of Clinical Oncology. 
The CTC is the statistical centre for GINECO’s 
CALYPSO, the largest international trial of therapy 
for relapsed ovarian cancer, with 976 patients 
worldwide. The CTC’s conducts its gynaecological 
trials in collaboration with the Australia New Zealand 
Gynaecological Oncology Group (ANZGOG), which 
participates in international trials such as CALYPSO. 
Streptomyces verticillus, source of bleomycin,  
used to treat testicular cancer  
(Reprinted with permission. By T Harada and M Hamada,  
©Society for Actinomycetes, Japan)
HIGH-Dose BLeoMYCIn, etoPosIDe AnD 
CIsPLAtIn (BeP) estABLIsHeD As tHe Best 
CHeMotHeRAPY FoR testICULAR CAnCeR
Testicular cancer is curable in over 95% of cases 
with treatment regimens that have been around for 
many years. A trial conducted in the early days of the 
CTC comparing a 3-cycle higher-dose BEP regimen 
with a 4-cycle lower-dose regimen showed after less 
than 3 years of follow-up that the former had better 
outcomes than the latter. Patients have continued 
to be followed up, and an analysis of their outcomes 
9 years later was published in the Journal of the 
National Cancer Institute. The survival rate continued 
to be better for patients treated with the shorter, 
more intense regimen. The study helped to establish 
the best regimen for testicular cancer, which is now 
included in clinical guidelines.
The CTC undertakes investigator-initiated trials 
with the Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP).
The thorough article by Grimison et al, with 
the careful attention to long-term follow-up, 
in our view, should bring an end to clinical 
investigations of alternatives…
— Nichols and Killmannsberger, editorial, 
JNCI, 18 August 2010.
‘ ‘
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CAnCeR oF tHe BILIARY tRACt  
AnD GALLBLADDeR
Billiary tract cancers have poor prognosis and 
short survival because most patients have 
advanced disease at diagnosis. There is no 
generally accepted standard treatment, and 
patients’ response to treatment varies according 
to the main site of the cancer: biliary tree or 
gallbladder. The AGITG and CTC conducted 
a phase II trial of chemotherapy to test the 
feasibility of fixed-dose-rate gemcitabine and 
cisplatin in 50 Australian and New Zealand 
patients with biliary tract or gallbladder cancer, 
which was published in Cancer Chemotherapy and 
Pharmacology. The treatment was well tolerated, 
and some tumours regressed in response to it, 
although fixed-dose-rate administration did not 
appear to be an advantage over regular infusion. 
tHe InteRnAtIonAL esPAC 3 tRIAL  
FoR PAnCReAtIC CAnCeR
Cancer of the pancreas is a challenging disease, 
with a poor 5-year survival rate. An international 
collaborative group involving the CTC and 
AGITG (with 16% of trial sites and 133 patients 
in Australia and New Zealand) completed a 
large study that compared two commonly 
used treatments with different modes of 
action—fluorouracil-based chemotherapy and 
gemcitabine. Survival was similar for patients 
in both arms of the trial: half of the patients in 
each arm of the trial survived for at least 2 years, 
showing that both treatments had benefit. 
The report, by the European Study Group for 
Pancreatic Cancer, was published in JAMA.
CARe AnD QUALItY oF LIFe:  
InPAtIent Vs oUtPAtIent CHeMotHeRAPY
Patients requiring high-dose chemotherapy have 
traditionally needed at least a night in hospital for 
therapy to help them cope with side-effects. Many 
hospitals have gradually shifted to outpatient 
treatment, but whether this suits the patients or has 
led to worse side-effects or emergency admissions to 
hospital has been unclear. 
A study by the Sydney Cancer Centre and the CTC 
compared inpatient and outpatient administration of 
high-dose cisplatin chemotherapy for lung, stomach, 
bladder and other cancers. Patients were randomly 
allocated to one of the two treatment settings for 
their first cycle and then crossed over to the other for 
the second cycle.
Outpatient treatment was preferred by most 
patients and appeared to be safe. After outpatient 
treatment, patients reported less distress about 
the thought of chemotherapy, but otherwise their 
perceived quality of life was not different.
Katrin sjoquist, AGItG and AnZGoG, clinical research fellow
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Dr Prunella Blinman
PReFeRenCes stUDIes: WHAt sURVIVAL BeneFIts 
MAKe CHeMotHeRAPY WoRtHWHILe?
Dr Prunella Blinman is undertaking a series of studies of how 
patients and their doctors trade off the benefits and harms of 
chemotherapy.
Chemotherapy is underutilised for non-small-cell lung cancer, 
the most common form of lung cancer, although it can improve 
5-year survival rates after operation by about 5% and 1-year 
survival rates of patients with advanced cancer by 9%. In an 
observational study, lung cancer clinicians were asked to rate the 
survival benefits that would make chemotherapy worthwhile. 
Their responses were widely varied and unrelated to other 
factors, but they judged very small improvements in survival as 
justifying chemotherapy.
In another recent study, a questionnaire was used to elicit 
survival and chemotherapy trade-off preferences from patients 
after the experience of chemotherapy for colon cancer. Many 
judged that small survival benefits made therapy worthwhile. 
These preferences studies underline the need for cancer 
clinicians to discuss the pros and cons of chemotherapy and 
allow patients’ views and values to influence decisions about 
treatment. 
CARe AnD QUALItY oF LIFe:  
LeARnInG ABoUt PAIn
A randomised trial has shown that people with pain 
from cancer can benefit from a simple educational 
intervention. People with advanced cancer are often 
undertreated for their pain, possibly because of their 
fears of opoid addiction. Learning more about pain 
from a booklet or video, or both, improved their pain 
scores and reduced their addiction fears.
FURtHeR AnALYsIs FRoM tRIALs FoR 
GAstRoIntestInAL stRoMAL tUMoURs
Data from a published AGITG–EORTC trial 
comparing high and low-dose imatinib treatment for 
gastrointestinal stromal tumours has been combined 
with the results of an American trial in MetaGIST, 
a meta-analysis showing that overall survival was 
similar for both dosage schedules (p.14).
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tHe ARt oF onCoLoGY: 
CoMMUnICAtInG sURVIVAL 
eXPeCtAnCY to PAtIents
How long do I have to live?
‘As training oncologists, we learn 
communication skills in a role-play situation 
but we are not taught what numbers to use 
in answer to that vital question.’
The critical question, ‘How long do I have to live?’, 
which a patient with advanced cancer inevitably 
asks their doctor, and the prognostic uncertainty 
that surrounds the answer, is the main topic of 
Dr Belinda Kiely’s doctoral research.
‘It is very difficult for oncologists to estimate 
the survival time for such patients and they 
invariably don’t know how best to communicate 
bad news—so they avoid it’, she says. ‘As training 
oncologists, we learn communication skills in a 
role-play situation but we are not taught what 
numbers to use in answer to that vital question’.
Dr Kiely’s goal is improving communication 
of life expectancy to patients in a way that is 
realistic but maintains hope. The median survival 
is the measure that most cancer professionals 
are familiar with, but for patients, the median 
is unnecessarily discouraging and frequently 
misinterpreted. Many patients interpret the 
median as a limit and do not realise that 50% live 
longer. Dr Kiely and her colleagues have suggested 
framing information in terms of the chance of 
Dr Belinda Kiely
surviving rather than the chance of dying as a 
way of conveying hope. They also suggest using 
multiples and fractions of the median to present 
typical, best-case and worst-case scenarios to 
patients, rather than just a single estimate of the 
median.
These conversations require data. The 
researchers sought this information from clinical 
trials of metastatic breast cancer. They were able 
to provide simple multiples from trial survival 
curves for clinicians to use to communicate typical, 
best-case and worst-case survival information 
for patients about to start chemotherapy for 
metastatic breast cancer. The results of this 
research and an essay to stimulate thought and 
discussion on this aspect of patient care have both 
been published in the Journal of Clinical Oncology.
The CTC is an ideal environment for a cancer 
researcher. Belinda has gained expertise and 
experience in statistics, as well as writing 
protocols, producing a budget and applying for 
funding. ‘I would not have been able to do it 
without the support of the biostatistics team and 
the trial groups at the CTC’ says Belinda. ‘Doctors 
who are doing their PhDs in other settings such as 
hospitals don’t have access to specialist expertise 
in publications, trials and statistics’. 
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PReDICtInG InDIVIDUAL sURVIVAL AnD 
tHe BeneFIts oF tReAtMent
Three years ago, Professor John Simes told a 
budding researcher, Dr Chee Lee, that biomarkers 
are the research of the future. Chee is now 
undertaking studies that use biomarkers and other 
information from clinical trials to predict survival 
and the benefits of different treatments for cancer 
patients, particularly women with breast or 
ovarian cancer.
It is possible to individualise cancer treatment 
by identifying biological biomarkers that signal 
that the patient will benefit. This is clearly good 
for the patient’s quality of life, and Chee’s quest is 
to find more treatments that suit each individual 
cancer patient, replacing the scattershot approach 
of one chemotherapy regimen for all.
‘Having access to patients’ tumour tissues 
donated as part of the clinical trial, we can narrow 
our research down to finding out where and why 
the drug worked. In the clinic, when you see a 
patient you ask: “Is there anything I can do to 
make it better?” Having access to these data helps 
me answer that question.’
The laboratory and data collection are done 
elsewhere, then data are analysed and managed 
within the CTC. 
Chee is passionate about his work. Before 
starting his PhD at the CTC, he did clinical training 
in hospitals and participated in distance learning 
programs in statistics and research methods. In 
mentoring his registrars, he makes a point that 
good training in research is important, as it helps 
to develop useful analytical skills. But research 
needs to have clinical relevance. ‘You can do 
wonderful analysis and come up with a nice paper, 
but doctors can tell you the theory doesn’t always 
apply in real life.’ 
‘I realise that if you don’t see patients, 
you don’t understand what is 
important in real life. ’ 
Dr Chee Lee
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ACHIeVeMents In  
CARDIoVAsCULAR DIseAse ReseARCH
PREVENTING CARDIOVASCULAR DISEASE
LonG-teRM InVestIGAtIon oF HeARt 
DIseAse PReVentIon
The Long-Term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) trial has reached 16 years 
of follow-up of patients treated for prevention 
of recurrent heart disease. Their outcomes are 
being analysed. Blood samples collected over the 
first six years of the trial are being analysed in the 
laboratories of collaborating scientists from Germany, 
Sweden and the United States, and are being used in 
a new round of investigations of how various blood 
components are related to, first, the risk of disease 
and, second, the effects of pravastatin.
FenoFIBRAte AnD eVent-LoWeRInG In DIABetes (FIeLD): FenoFIBRAte PRoteCts AGAInst 
AMPUtAtIon, RetInAL DIseAse, AnD noW, KIDneY DIseAse
The FIELD trial enrolled 9795 patients with type 2 diabetes from Australia, New Zealand and Finland, who 
were randomly allocated for fenofibrate or placebo.
The trial closed in 2005 and has already resulted in over 20 peer-reviewed research papers, with many 
substudies under way. These include long-term follow-up of patients and translational studies in which 
assays of blood samples will help to reveal molecular and genetic biomarkers of diabetes and the pathways 
of action of fenofibrate, new knowledge that will ultimately benefit people with diabetes in the future.
Substudies of FIELD patients have previously shown that the study drug, fenofibrate, is beneficial 
for people with diabetes in terms of reducing the need for amputations and for laser treatment of eyes. 
That is, fenofibrate is good for disease of the small blood vessels. Two recent renal studies completed the 
microvascular-disease trio, showing, first, that mild renal impairment predicts 
later cardiovascular events and, second, that fenofibrate treatment may reduce 
loss of kidney function. These were published in Diabetologia.
ReCURRent VenoUs tHRoMBoeMBoLIsM
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE), a trial that aims 
to determine whether low-dose aspirin prevents 
recurrence of venous thromboembolism, is 
an international trial coordinated by the CTC. 
The trial currently has 767 patients, from 
Australia, New Zealand, Singapore, the United 
Kingdom, India and Argentina. The ASPIRE 
investigators are collaborating with investigators 
from Italy (WARFASA trial) in the INSPIRE 
prospective meta-analysis, led by the Australian 
investigators.
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MICe AnD Men: LABoRAtoRY 
ReseARCH eXtenDInG tHe  
FIeLD tRIAL ResULts
Diabetes is a systemic condition with 
various destructive effects on blood 
vessels and nerves. Patients are at risk of 
leg ulcers because of poor circulation and 
poor sensation. If the ulcers fail to heal 
properly, there is risk of infection leading to 
osteomyelitis (inflammation of the bone) 
or gangrene of the foot, which may require 
amputation of the toes or foot.
A substudy of the FIELD trial showed that 
fenofibrate treatment reduces amputations. 
Dr Kushwin Rajamani is now attempting 
to find the mechanisms of this effect in 
laboratory mice with diabetes, as part of his 
PhD research. He is studying the effects of 
fenofibrate on various cell functions that may 
be involved in the effects of fenofibrate. 
Kushwin says: ‘Since I was an intern I 
have been passionate about cardiology 
and wanted to be a cardiologist. I enjoy 
the physiology, the cardiovascular 
pharmacology, as well as caring for patients 
with cardiovascular problems and improving 
patients’ wellbeing in many situations. I 
also enjoy the research and evidence-based 
medicine in cardiology.
‘At the CTC I have had the opportunity 
to work with world-class leaders in the 
field who have taught me the principles 
behind epidemiological research, and the 
statisticians have helped me tremendously 
with the analyses. My supervisors have 
been very supportive throughout my time 
here, and have helped me grow my research 
abilities.’
‘Since I was an intern I have 
been passionate about 
cardiology and wanted 
to be a cardiologist. I 
enjoy the physiology, the 
cardiovascular pharmacology, 
as well as caring for patients 
with cardiovascular problems 
and improving patients’ 
wellbeing in many situations. 
I also enjoy the research and 
evidence-based medicine.’
Dr Kushwin 
Rajamani
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InteRnAtIonAL DIFFeRenCes AnD 
RIsK MoDeLs FoR ACUte MYoCARDIAL 
InFARCtIon
Rachel o’Connell began her association with the 
CTC working as a biostatistician with Professor 
Malcolm Hudson on a large international trial, 
HERO-2. A trial substudy raised new questions 
which led her to study the topic further as a PhD 
student. 
The Hirulog and Early Reperfusion or Occlusion 
(HERO-2) trial, a VIGOUR collaborative trial, 
randomised 17 073 patients in 46 countries to 
treatment for myocardial infarction. In this trial, 
mortality rates across 5 geographical regions 
(Western countries, Latin America, Eastern 
Europe, Russia and Asia) varied considerably, 
with lower rates in western countries. Rachel 
attempted to find explanations for these 
differences in mortality, such as patient case-mix, 
treatments, and national health and economic 
statistics. The study was published in 2010 in the 
American Heart Journal.
 ‘The CTC is an excellent place to do research as 
there are so many gifted people with varying 
research backgrounds and strengths who are 
willing to help when problems arise, share ideas 
and offer interesting perspectives. The standard 
of intellectual contribution and creative thinking 
among the statistics group is exceptional. ‘
She also developed a comprehensive, 
international risk model to identify significant 
predictors of 30-day mortality after myocardial 
infarction.
Now reaching the end of her PhD, Rachel says: 
‘The fact that we had data from so many countries 
and observed such large variations in outcome 
rates which weren’t explained by differences 
in patient baseline risk was interesting. This is 
a public health concern. Another interesting 
finding was that predictors of survival were very 
consistent across all regions despite the differences 
in outcome rates.
 ‘The CTC is an excellent place to do research 
as there are so many gifted people with varying 
research backgrounds and strengths who are 
willing to help when problems arise, share ideas 
and offer interesting perspectives. The standard 
of intellectual contribution and creative thinking 
among the statistics group is exceptional. This 
environment has fostered a culture of learning 
and personal development and has cultivated the 
research and statistical skills that I have today’.
Rachel o’Connell
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Preventing cardiovascular disease
CLInICAL AnD LABoRAtoRY ReseARCH 
on DIABetIC KIDneY DIseAse
Dr Ru-Dee ting’s PhD project is on the 
microvascular complications of diabetes. In 
clinical studies based on the FIELD trial, he is 
examining various markers that might predict 
kidney disease. He is also elucidating by laboratory 
research how fenofibrate benefits the kidneys. This 
seems to involve multiple pathways and is not as 
straightforward as was initially thought.
 ‘If we have a greater understanding of how 
fenofibrate works we can then develop other drugs 
that can better target those parts and produce 
better efficacy in preventing renal disease’, says 
Ru-Dee. 
The opportunity for Ru-Dee to embark on a PhD 
presented itself when he worked as an advanced 
trainee cardiologist at Royal Prince Alfred Hospital 
on a small project with Professor Tony Keech. 
‘CTC has excellent facilities, supportive staff and 
an army of statisticians to help out. Expertise in 
statistics is not available to every research group; 
they either have to do their own, or send their 
data to a part-time statistician. To be able to walk 
across the floor and have a chat with a statistician 
at CTC is very useful. It is much more effective than 
just getting a P value.’
‘If we have a greater understanding 
of how fenofibrate works we can 
then develop other drugs that 
can better target those parts and 
produce better efficacy in preventing 
renal disease’ 
Dr Ru-Dee ting
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The CTC works with organisations around the world in collaborations that lead to better health outcomes in 
Australia and internationally. New collaborations are continually sought and then consolidated in research 
projects benefiting the health of Australians and others. 
GRoUP nAtURe oF GRoUP ACtIVItY
A la CART and Z6094 US study meta–analysis Meta-analysis collaboration: international Member
AMICABLE collaboration Meta-analysis collaboration: international Member
ANZ Breast Cancer Trials Group (ANZ BCTG) Collaborative group for breast cancer trials: Australia, New Zealand
International collaborations: International Breast Cancer Study 
Group (IBCSG), Breast International Group (BIG), International 
Breast Cancer Intervention Study (IBIS)
Statistical centre for group, including 
randomisation
ANZ Germ Cell Tumour Study Group (ANZ GCTG) Collaborative group for testicular cancer trials: Australia,  
New Zealand
Coordinating centre
ASPIRE Study Group Collaborative group for ASPIRE trial: Australia, New Zealand,  
United Kingdom, India, Argentina
Coordinating centre
Australasian Gastro-Intestinal Trials Group 
(AGITG)
Collaborative group for gastrointestinal cancer trials: Australia,  
New Zealand
International collaborations: NSABP (USA), ECOG (USA), EORTC 
(Europe), PETACC (Europe), NCIC CTG (Canada), OCTO (UK)
Coordinating centre
Australian and New Zealand Urogenital and 
Prostate Clinical Trials Group (ANZUP)
Collaborative group for cancer of the genitourinary system Coordinating centre
Australasian Society of Thrombosis and 
Haemostasis
Professional group undertaking thrombosis trials: Australia,  
New Zealand
Coordinating centre
Australasian Lung Cancer Trials Group (ALTG) Collaborative group for lung cancer trials 
International collaborations: NVALT (Netherlands),  
NCIC CTG (Canada)
Coordinating centre
ANZ Gynaecological Oncology Group (ANZGOG) Collaborative group for gynaecological cancer trials: Australia,  
New Zealand
International collaborations: Gynecological Cancer Intergroup 
(GCIG), International Gynaecological Cancer Intergroup (IGCI), 
Gynecologic Oncology Group (GOG)
Coordinating centre
Australian New Zealand Clinical Trials Registry 
(ANZCTR)
National register of Australian clinical trials Coordinating centre
Australian universities University members of Biostatistics Collaboration of Australia Coordinating centre
Cochrane Collaboration Collaborative group undertaking systematic reviews of  
trial evidence: international
Editorial base of the Cochrane Breast 
Cancer Group; co-convening centre for 
Prospective Meta-analysis Methods Group
Cochrane Prospective Meta-Analysis Methods 
Group
Cochrane group ; international Coordinating centre
Cholesterol Treatment Trialists’ Collaboration 
(CTTC)
Collaboration of clinical trial groups studying cholesterol treatments: 
Australia, New Zealand, United Kingdom, United States, Italy
Coordination of meta-analyses in heart 
disease
Clinical Trial Development Unit Joint venture with Peter MacCallum Cancer Institute Statistical support for cancer trials
Cooperative Trials Group for Neuro-Oncology 
(COGNO)
Collaborative group for brain cancer trials Coordinating centre
Medical Services Advisory Committee Department 
of Health and Ageing
Government: Australia Provide assessments of new technologies 
and other research services
BCA: biostatistics education
EPOCH collaboration Prospective meta-analysis collaboration: international Data coordination centre
European Organisation for Research and 
Treatment of Cancer (EORTC)
International collaborative group Collaborator through Australian groups
COLLABORATIONS
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Collaborations
GRoUP nAtURe oF GRoUP ACtIVItY
FIELD Study Group Collaborative group for FIELD diabetes trial: Australia, New Zealand, 
Finland
Coordinating centre
Gynaecologic Cancer Intergroup (GCIG) International collaborative group Collaborator through ANZGOG
Gynecologic Oncology Group (GOG) International collaborative group Collaborator through ANZGOG
INIS Study Group Collaborative group for INIS trial: Australia, New Zealand,  
United Kingdom
Regional coordinating centre
INSPIRE Meta-analysis: ASPIRE and WARFASA (Italy) Member
LIPID Study Group Collaborative group for follow-up and genetic studies of LIPID 
cholesterol-lowering trial: Australia, New Zealand, Germany
Coordinating centre
Meta-Analysis of Preterm Patients on Inhaled 
Nitric Oxide (MAPPiNO ) collaboration
Meta-analysis collaboration: international Data coordination centre
Medical Research Council (MRC) Government: international Collaborator
Menzies Research Institute and Charles Darwin 
University
Research institution: Australia Collaborator 
National Cancer Institute of Canada Clinical Trials 
Group (NCIC CTG)
Trials research group: Canada Collaborator through Australian cancer 
collaborative groups
National Heart Foundation Nongovernment organisation: Australia Coordinator of the LIPID trial
National Perinatal Epidemiology Unit (NPEU), 
University of Oxford
Research institution: UK Co-collaborator on the INIS neonatal trial
National Surgical Adjuvant Breast and Bowel 
Project (NSABP)
Collaborative group Collaborator through Australian groups
Neonatal Oxygenation Prospective Meta-analysis 
(NeOProM) collaboration
Prospective meta-analysis collaboration; international Coordinating centre
NSW Cancer Council Cancer Epidemiology Research Unit Collaborator
NSW Cooperative Oncology Group Collaborative group: NSW Coordinating centre for the group
Oxford Clinical Trials Office (OCTO) Trials research group: UK Cancer trials
Perinatal Antiplatelet Review of International 
Studies (PARIS) collaboration
Meta-analysis collaboration with representation from  
many countries
Co-coordinating centre
PRECISE collaboration Meta-analysis collaboration: international Member
Prevention of Ventilator Induced Lung Injury 
collaborative study group (PreVILIG) 
Meta-analysis collaboration: international Data coordination centre
PRECISE collaboration Meta-analysis collaboration; international Member
Primary Care Cancer Trials Group Collaborative group: Australia Collaborator
Primary Coronary Angioplasty versus 
Thrombolysis (PCAT)
Meta-analysis collaboration with representation from  
many countries
Co-coordinating centre
Prospective Pravastatin Pooling project Collaborative group: Australia, New Zealand, United States, Scotland Coordinating centre
Royal Australasian College of Surgeons (RACS) Professional society undertaking trials of surgery: Australia and  
New Zealand
Coordinating the SNAC trial in breast 
cancer with the RACS
Star Child Health International collaboration Member
VIGOUR group Collaborative group for trials of heart disease: 40 countries Data coordinating centre, Asia-Pacific 
Region; International statistical centre 
(HERO-2 trial)
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tRIAL PARtICIPAnts tARGet ACCRUAL
neonatal disorders
Current trials
BOOST II: Benefits of oxygen saturation targeting Neonates born before 28 weeks’ gestation  1200 1135
APTS: Australian placental transfusion study Neonates born before 30 weeks’ gestation  1600 6
Trials in follow-up
INIS: International neonatal immunotherapy study Neonates with infection and low birthweight who 
are taking antibiotics
1500 (ANZ); 
3500 (international)
1398 (ANZ);  
3493 (international)
Cardiovascular disorders
Current trials
ASPIRE: Aspirin to prevent recurrent venous 
thromboembolism
People who have had 6 months of treatment with 
warfarin for a venous thromboembolism
 1200 (international) 671 (ANZ);  
767 (international)
Trials in follow-up
FIELD: Fenofibrate intervention and event lowering in 
diabetes
Patients with type 2 diabetes 8000 9795
LIPID: Long-term intervention with pravastatin in ischaemic 
disease
Patients with a history of coronary heart disease 9000 9014
Breast cancer
Current trials
SNAC 2: Multicentre randomised trial of sentinel-node 
biopsy versus axillary clearance 
RACS and NHMRC CTC study
Women with operable breast cancer, stratified by 
various factors, including age and tumour size
Women with operable breast tumours up to 3 cm
 1012 146
Trials in follow-up
SNAC 1: Sentinel node biopsy versus axillary clearance 
RACS and NHMRC CTC study
Women with operable breast cancer, stratified by 
various factors, including age and tumour size
1000 1088
Gastrointestinal cancer
Current trials
A la CART: Australian phase III randomised trial of 
laparascopy-assisted resection compared with open 
resection (AG0109CS )
AGITG study
Patients with primary rectal cancer 470 (ANZ); 13
ATTAX 3: Phase II study of docetaxel, cisplatin and 
fluoropyrimidine with or without panitumumab for 
oesophagogastric cancer (AG0607OG) 
AGITG study
Patients with metastatic or locally recurrent 
oesophagogastric cancer
100 20
LAP07: randomised multicentre phase III study of 
gemcitabine with or without chemoradiotherapy and with 
or without erlotinib for adenocarcinoma of the pancreas 
(AG0208PS) 
AGITG and GERCOR study
Patients with locally advanced adenocarcinoma 
of the pancreas
60 (ANZ);  
900 (international
5 (ANZ)
PETACC 6: addition of capecitabine to preoperative 
oxaliplatin chemoradiotherapy and postoperative oxaliplatin 
chemotherapy for rectal cancer (AG0707R) 
EORTC study
Patients with locally advanced rectal cancer 100 60
CURRENT TRIALS AT THE CTC
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Current trials at the CTC
tRIAL PARtICIPAnts tARGet ACCRUAL
REGISTER: multicentre phase II study of risk evaluation 
in GIST with selective therapy escalation for response 
(AG0507GS) 
AGITG study
Patients with gastrointestinal stromal tumour not 
suitable for curative surgery
80 19
SCOT: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer (AG0308CR) 
AGITG study
Patients with fully resected stage III colorectal 
cancer
225 (ANZ);  
9500 (international)
11
SUPER: Phase III trial evaluating surgical resection of the 
primary tumour in metastatic colorectal cancer  
(AG 0209CRS)
Patients with unresectable metastatic colorectal 
cancer
30 (stage 1);  
400 (full trial)
3
SURGIST: Phase III randomised study of surgery of residual 
disease (AG0108GS) 
EORTC study
Patients with metastatic gastrointestinal stromal 
tumour responding to Imatinib mesylate
35 (ANZ);  
350 (international)
0
TOP GEAR: randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for 
gastric cancer (AG0407GR, TROG 08.08) 
AGITG study
Patients with resectable gastric cancer suitable for 
these treatments
120 (stage 1);  
632 (stage 2)
12
Pending trials
ATTACHE: timing of surgery and adjuvant chemotherapy for 
hepatic colorectal metastases 
AGITG study
Patients with confirmed resectable liver 
metastases and no other disease
200
PAN1: phase II study evaluating potential predictive 
biomarkers and examining the efficacy and safety of 
mFOLFOX6 compared to gemcitabine for pancreatic cancer 
AGITG study
Patients with confirmed metastatic pancreatic 
adenocarcinoma
80
Trials in follow-up
C07: 5-fluorouracil plus leucovorin compared with 
oxaliplatin with 5-fluorouracil + for stages II and III 
carcinoma of the colon 
NSABP study
Patients with resected stage II or stage III colon 
carcinoma
150 134
CO.20: phase III study of BMS-582664 with cetuximab 
versus placebo with cetuximab 
NCIC CTG and AGITG study
Patients with metastatic colorectal carcinoma 
previously treated with combination 
chemotherapy
370 (ANZ);  
750 (international)
416 (ANZ);  
686 (international)
EORTC 62005: Phase III study of two different doses of 
imatinib mesylate for CD117-expressing metastatic or 
unresectable gastrointestinal stromal tumour
EORTC study
Patients with metastatic gastrointestinal stromal 
tumour
80 (ANZ);  
600 (international)
116 (ANZ);  
946 (international)
EORTC 62024: Randomised trial of adjuvant imatinib 
mesylate (Glivec) versus no further therapy after complete 
surgery 
EORTC study
Patients with fully resected gastrointestinal 
stromal tumour
8 (ANZ);  
80 (international)
6 (ANZ);  
81 (international)
Quasar 2: phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer (AG0107CR) 
OCTO study
Patients with colon cancer treated by surgery 120 219 (ANZ);  
1179 (international)
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Gynaecological cancer
Current trials
PORTEC 3: Phase III trial comparing concurrent 
chemo¬radiation and adjuvant chemotherapy with pelvic 
radiation alone in high-risk endometrial carcinoma (TROG 
08.04) 
CGOG and ANZGOG study
Women with advanced endometrial carcinoma  200 (ANZ);  
500 (international)
50 (ANZ);  
300  (international)
Symptom benefit: Palliative chemotherapy for ovarian 
cancer (ANZGOG0701 )
ANZGOG and PoCoG study
Women with platinum-resistant epithelial ovarian 
cancer
 100 92
Accelerated BEP: Feasibility study of accelerated BEP as 
first-line chemotherapy for advanced germ cell tumours 
(ANZGCTG0206, ANZGOG0603) 
ANZUP and ANZGOG study
Patients with intermediate and poor-risk 
advanced germ cell tumours (and selected  
good-risk tumours)
 25 45
Pending trials
ICON 6: Placebo-controlled trial of concurrent cediranib and 
chemotherapy versus chemotherapy alone (stage 2) and 
of maintenance cediranib versus placebo after concurrent 
cediranib and chemotherapy (stage 3) 
ANZGOG study
Women with platinum-sensitive relapsed ovarian 
cancer
 100 (stage 2);  
400 (stage 3)
Outback: Phase III trial of addition of adjuvant chemotherapy 
to standard chemoradiation as primary treatment for 
cervical cancer 
ANZGOG study
Women with locally advanced cervical cancer  780
PARAGON: phase II study of anastrozole in gynaecological 
cancers 
GCIC study
Women with potentially hormone-responsive 
gynaecological cancers
 100 (ANZ)
Trials in follow-up
TRIPOD: Phase II trial of intraperitoneal chemotherapy 
(ANZGOG 0601) 
ANZGOG study
Women with ovarian and related cancers 35–100 39
OVAR 16: Phase III study of pazopanib versus placebo for 
epithelial ovarian, fallopian tube or primary peritoneal cancer 
ANZGOG study
Women with stage II–IV ovarian fallopian tube or 
primary peritoneal cancer that has not progressed 
after first-line treatment
65 50
ICON 7: Randomised, two-arm, multicentre trial of adding 
bevacizumab to standard chemotherapy for epithelial 
ovarian cancer 
GCIG study
Women with epithelial ovarian cancer who have 
not received systemic antitumour therapy
100 76
SCOTROC 4: Multicentre randomised trial of carboplatin 
flat dosing vs intrapatient dose escalation in first-line 
chemotherapy 
Women with ovarian, fallopian tube or  
peritoneal carcinoma who are unsuitable for 
platinum–taxane therapy
150 (ANZ);  
1300 (international)
64 (ANZ);  
937 (international)
Tarceva: phase III study of erlotinib versus observation 
(EORTC 55041)
Women with high-risk stage I or stages II–IV 
ovarian cancer which has not progressed after 
platinum chemotherapy
80 42
Phase III randomised trial of paclitaxel + carboplatin versus 
triplet or sequential doublet combinations for epithelial 
ovarian or primary peritoneal carcinoma (GOG 182)
Women with advanced (stage III or IV) primary 
ovarian or peritoneal cancer
400 183
Prospective study of risk-reducing salpingo-oophorectomy 
and longitudinal CA-125 screening among women at 
increased genetic risk of ovarian cancer (GOG 199)
Women aged >30 at risk of ovarian cancer 250 83
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Genitourinary cancer
Current trials
Accelerated BEP: feasibility study of accelerated BEP as 
first-line chemotherapy for advanced germ cell tumours 
(ANZGCTG 0206, ANZGOG 0603) 
ANZUP and ANZGOG study
Patients with intermediate and poor-risk 
advanced germ cell tumours (and selected good-
risk tumours)
25 45
Aprepitant for germ cell chemotherapy: phase II 
multicentre trial of a 7-day aprepitant schedule to prevent 
chemotherapy-induced nausea and vomiting (ANZGCTG 
0801) 
ANZUP study
Patients receiving cisplatin-based chemotherapy 
for germ cell tumours
 50 50
Chemo & cognition: cognitive function and treatment for 
testicular cancer (ANZGCTG 0106) 
ANZUP study
Patients being treated and followed up for 
testicular cancer
154 121
Eversun: phase II trial of everolimus alternating with 
sunitinib for renal cell carcinoma (ANZUP 0901) 
ANZUP study
Patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 2
SORCE: Adjuvant sorafenib for renal cell carcinoma (RE 05) 
MRC (UK) and ANZUP study
Patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ); 
1656 (international)
30 (ANZ)
Lung cancer
Current trials
B2P2M2: phase II trial of BNC105P as second-line 
chemotherapy for pleural mesothelioma (ALTG 09/004)
Patients with pleural mesothelioma which has 
progressed after pemetrexed and platinum 
chemotherapy
 60 6
BR.26: phase III trial of PF-804 in patients with incurable, 
non-small cell lung cancer (ALTG 09/002)
Patients with stage IIIB or IV non-small-cell lung 
cancer
180 2 
BR.29: cediranib versus placebo for patients receiving 
paclitaxel and carboplatin for non-small-cell lung cancer 
(ALTG 09/001) 
NCIC CTG and ALTG study
Patients with stage IIIB or IV non-small-cell lung 
cancer
100 75
NITRO: phase III multicentre trial of adding nitroglycerine 
to first-line chemotherapy for advanced non-small-cell lung 
cancer (ALTG 06/003) 
ALTG study
Patients with advanced non-small-cell lung 
cancer
 500 71
PACT in NSCLC: Preferences for adjuvant chemotherapy in 
non-small-cell lung cancer (04/009) 
ALTG study
Patients with non-small-cell lung cancer, 
surgeons and oncologists
 200 42
Trials in follow-up
MATES: Maintenance thalidomide in mesothelioma 
NVALT, ALTG study
Patients with malignant pleural mesothelioma, 
after first-line chemotherapy
100 (ANZ);  
200 (international)
14
Brain cancer
Current trials
CATNON: Phase III trial of concurrent and adjuvant 
temozolomide chemotherapy anaplastic glioma (EORTC 
26053-22054) 
EORTC study
Patients with non-1p/19q- deleted anaplastic 
glioma
100 (ANZ);  
748 (international)
0
LGG: Phase III study of primary chemotherapy with 
temozolomide versus radiotherapy for low-grade glioma 
(TROG 06.01) 
COGNO and TROG study
Patients with low-grade glioma, stratified for 
genetic 1p loss
100 (ANZ); 
466 (international)
36 (ANZ);  
466 (international)
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Phase III study of temozolomide and short-course radiation 
versus radiation alone for glioblastoma multiforme in elderly 
patients (TROG 08.02) 
COGNO and TROG study
Elderly patients with new glioblastoma 
multiforme
100 (ANZ);  
500 (international)
41 (ANZ);  
251 (International)
Pending trials
Cabaret: phase II study of carboplatin and bevacizumab in 
for glioma 
COGNO study
Patients with recurrent grade IV glioblastoma 
multiforme following radiotherapy and 
temozolomide chemotherapy
 120
Phase II study of acetazolamide plus dexamethasone versus 
dexamethasone for cerebral oedema in glioblastoma 
COGNO study
Patients with glioblastoma requiring new 
dexamethasone or dose increase due to 
progressive or recurrent disease
 86
Phase II study of psycho-educational intervention in patients 
with primary brain tumour 
PoCoG led, COGNO cobadged study
Patients with confirmed primary brain tumours  60
Funding
FUnDeR $
NHMRC
 Program grant 1 604 545
 Fellowships 390 275
 Project grants for trials 3 306 937
 Grants for Infrastructure 553 545
Cancer Australia, Cancer Institute and cancer councils
 Trials 1 582 432
 Infrastructure 3 988 745
National Heart Foundation 64 500
Public funding for health economics 118 774
Public funding for systematic reviews 1 257 354
Pharmaceutical companies, primarily for trials* 5 572 170
Consulting and donations 52 478
Other 1 404 657
total 19 896 412
* Amgen, Arcagy-Gineco, Bayer, Bionomics Ltd, Bristol-Myers Squibb, Fournier, Solvay Abbott, GlaxoSmithKline, Merck, Merck Sharp & Dohme, 
Pfizer Canada, Novartis, Roche
Current trials at the CTC and funding
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director and principal research fellow
Wendy Hague, MB BS, MBA, PhD, director, 
clinical trials program, and senior research 
fellow
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professor
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program manager, AGITG
Ann Livingstone, RN, MHlthServMgt, 
associate program manager, COGNO
Julie Martyn, BSc, GradDip HortSc, PhD, 
associate program manager, ANZGOG
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BOOST II trial
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Psychol, MRQA, clinical trials auditor
CLINICAL DATA MANAGEMENT
Mark Maclean, BA, DCR(T), CM, head
Nancy Guindi, BAppSc ,GradDip IT, clinical 
data project manager
Dena Hughes, BA, DBcert, MCP, clinical data 
project manager (to Nov 2010)
Liam Murphy, BSc, clinical data coordinator 
(from Jun 2010)
Michelle Cummins, BSc, PhD, clinical data 
project manager (from Sep 2010)
SITE MANAGEMENT
Rebecca Mister, BSc, MSc, head
SYSTEMATIC REVIEWS AND HEALTH 
CARE ASSESSMENT
Lisa Askie, BN, MPH, PhD, director, and senior 
research fellow
Angela Carberry, BAppSc, BHlthSc(hons), 
project officer
Jenny Chow, AssocDip, executive officer
Kylie Hunter, BA, BA(hons), project officer
Henry Ko, BEng(Med)(hons), PhD, project 
officer
Sally Lord, MB BS, DipPaed, MS, FRACGP, 
epidemiologist and senior research fellow
Lukas Staub, Dr med, DAS, project officer and 
PhD student
Fergus Tai, BAppSc, DipIT, MPH, project officer
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Medical Services Advisory Committee 
review group
Samara Lewis, BA/BSc(hons), PhD, project 
manager
Heather Gilbert, BA (hons), research officer
Merel Kimman, MSc, PhD, health economist
Henry Ko, BEng(Med)(hons), PhD, project 
officer
Luke Marinovich, BA(hons), MPH, project 
manager
Stephanie Schoeppe, MSocSc, project officer
Sally Wortley, BHlthSc(hons), MPH, Grad 
CertHlthEcon, project officer
Cochrane Breast Cancer review group
Melina Willson, BSc (hons)/BA, PhD, project 
manager
Fergus Tai, BAppSc, DipIT, MPH, project officer
Australian New Zealand Clinical Trials 
Registry
Kylie Hunter, BA, BA(hons), project officer
Henry Ko, BEng(Med)(hons), PhD, project 
officer
William Ooi, MHlthSc, BAppSc, project officer
Fergus Tai, BAppSc, DipIT, MPH, project officer
Thuyen Vu, BSc, IT project officer
HEALTH ECONOMICS
Deborah Schofield, BSpPath, GradDipComp, 
PhD, professor
Emily Callander, BA, research officer
Merel Kimman, MSc, PhD
Rupendra ShresthaMSc, PhD, research fellow
Hannah Verry, BEc, health economist
BIOSTATISTICS AND CONSULTING
Val Gebski, BA, MStat, professor and principal 
research fellow
Malcolm Hudson, BSc(hons), PhD, honorary 
professor
Ian Marschner, BSc(hons), PhD, professor
Kew Flood, administrative officer
Senior biostatisticians
Karen Byth, BSc(hons), MSc, PhD, DIC, CStat 
RSS, senior lecturer
Adrienne Kirby, BSc(hons), MSc, senior 
lecturer
Andrew Martin, BA, MA, GradDip, PhD, AStat, 
senior lecturer
Research fellows
Christopher Brown, BSc
Diana Zannino, BSc(hons), MSc
Biostatisticians
Elizabeth Barnes, BAppSc, MStat
Mark Chatfield, BA, MSc
Mark Donoghoe, BSc(hons)
Kristy Mann, BScAgr(hons)
Rachel O’Connell, BMath, MMedStat
Anne-Sophie Veillard, BSc, MSc
Merryn Voysey, GradDipMathStat, MBiostat
Biostatistics Collaboration of Australia 
(BCA)
Erica Jobling, executive officer
INFORMATION SYSTEMS
Infrastructure
Dinh Tran, BMath, MCompSc, infrastructure 
manager
Asanka Perera, BSc, computer systems officer
Thuyen Vu, BSc, computer systems officer
Database administration
Anh Tai Nguyen, BMath, database manager
Software development
Colin Sutton, BSc, MSc, IT systems 
development manager
Seshu Atluri, BE, software engineer
Ravinder Singh, BTech, software engineer
BUSINESS ADMINISTRATION
Kim Russell-Cooper, BA(hons), MBA, general 
manager
Cynthia Carr, BEd, HRD, human resources and 
administration manager
Suzanne Everett, BSW, human resources and 
administration coordinator
Maki Joseph, DipEd, finance officer
Thalia Hambides, executive assistant to the 
director
Agnes Ho, MPracAcc, CPA, finance officer
Jackie McGrath, administrative assistant
Faith Papuni, executive assistant to the deputy 
director
Frank Schoenig, administrative assistant
Bebe Sim, MAcc, CPA, finance manager
Carlos Sterling, BEng, MBA, finance officer
Nina Stromqvist, BFA(hons), grants 
coordinator
PUBLICATIONS
Rhana Pike, MA, GradCert, ELS, CMPP, senior 
publications officer
RESEARCH STUDENTS
Prunella Blinman, BMed, FRACP
Peter Grimison, BSc(Med), MB BS(hons), 
FRACP, PhD
Chee Lee, MB BS(hons), MMedSc, MBiostat, 
FRACP
Belinda Kiely, BSc(Med), MB BS, FRACP
Annette Kifley, MB BS, MAppStat
Kushwin Rajamani, MB BCh
Michaella Smith, BSc, MB BS(hons), MMSc
Rachel O’Connell, BMath, MMedStat
Lukas Staub, Dr med, DAS
Ru-Dee Ting, MB BS, FRACP
ACADEMIC STAFF
Lisa Askie, BN, MPH, PhD, senior research 
fellow
Christopher Brown, BSc, research fellow
Karen Byth, BSc(hons), MSc, PhD, DIC, CStat 
RSS, senior lecturer
Corona Gainford, MB BCh, BAO(hons), MSc, 
MRCP (UK), clinical research fellow
Val Gebski, BA, MStat, principal research 
fellow and professor
Wendy Hague, MB BS, MBA, PhD, senior 
research fellow
Anthony Keech, MB BS, MSc, FRACP, principal 
research fellow and professor
Merel Kimman, MSc, PhD, research fellow
Adrienne Kirby, BSc(hons), MSc, senior 
lecturer
Sally Lord, MB BS, DipPaed, MS, FRACGP, 
senior research fellow
Andrew Martin, BA, MA, GradDip, PhD, AStat, 
senior lecturer
Deborah Schofield, BSpPath, GradDipComp, 
PhD, professor
John Simes, BSc(Med)(hons), MB BS(hons), 
MD, SM, FRACP, senior principal research 
fellow and professor
Martin Stockler, MB BS(hons), MSc, FRACP, 
associate professor
Sonia Yip, BSc(hons), PhD, senior research 
fellow
Diana Zannino, BSc(hons), MSc, research 
fellow
Honorary associates of the CTC
Dr Meera Agar, COGNO
Dr Sally Baron-Hay, ANZGOG
Dr David Bernshaw, ANZGOG
Dr Andrew Berry, BOOST II
Dr Andrew Biankin, AGITG
Dr Alex Boussioutas, AGITG
Dr Alison Brand, ANZGOG
Dr Timothy Brighton, ASPIRE
Dr Michael Brown, ALTG
Dr Ian Campbell, SNAC 2
Professor Christopher Christophi, AGITG
Professor Forrester Cockburn, BOOST II
Dr Andrew Davidson, ALTG, AGITG
Associate Professor Ian Davis, ANZUP
Professor Catherine D’Este, BOOST II
Dr Jayesh Desai, AGITg
Dr Katherine Drummond, COGNO
Dr Vlatka Duric, Preferences studies
Dr John Eikelboom, ASPIRE
Dr Jonathan Fawcett, AGITG
Dr Kathryn Field, COGNO
Professor Michael Friedlander, ANZGOG
Professor Alexander Gallus, ASPIRE
Dr Davina Ghersi, ANZCTR
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Associate Professor P Grantley Gill, SNAC
Professor David Goldstein, AGITG
Dr Geraldine Goss, ANZGOG
Dr Michelle Grogan, ANZGOG
Dr Andrew Haydon, AGITG SCOT
Dr Elizabeth Hovey, ANZUP
Dr Monika Janda, COGNO
Dr Michael Jefford, AGITG SCOT
Dr David J Joseph, COGNO
Dr Andrew Kneebone, AGITg
Dr Eng-Siew Koh, COGNO
Ms Robyn Leonard, COGNO
Dr Trevor Leong, AGITG
Ms Karen Livingstone, ANZGOG
Dr Elizabeth Lobb, COGNO
Professor G Bruce Mann, AGITG
Dr Nicole McCarthy, ANZGOG
Dr Sue-Anne McLachlan, ALTG
Dr Michael Michael, AGITG
Dr Linda Mileshkin, AGITG
Professor Michael J Millward, ALTG
Dr Jeremy Millar, START
Dr Christopher Milross, ANZGOG
Professor Anna Nowak, COGNO
Professor Andreas Obermair, LACE
Dr Robert Padbury, AGITG
Professor Lyle Palmer, COGNO
Dr Nicholas J Petrelli, AGITG
Dr Cameron FE Platell, AGITG
Associate Professor Timothy J Price, AGITG
Professor Michael Quinn, ANZGOG
Dr David T Ransom, AGITG
Dr Danny Rischin, ANZGOG
Dr Mark Rosenthal, COGNO
Dr Gail Ryan, COGNO
Dr Eva Segelov, AGITG
Dr Jennifer A Shannon, AGITG
Dr Bernard M Smithers, AGITG
Dr Benjamin Solomon, ALTG
Dr Nigel A Spry, AGITG
Dr Christopher Steer, ANZGOG
Dr Andrew R Stevenson, AGITG
Mr John Stubbs, ANZUP
Professor Christopher Sweeney, ANZUP
Associate Professor Niall Tebbutt, AGITG
Professor Damian Thomson, ANZUP
Associate Professor Guy Toner, ANZUP
Dr Paul Vasey, ANZGOG
Dr Michell Vaughan, ANZGOG
Dr David G Walker, COGNO
Dr Euan Walpole, AGITG
Dr Neil Wetzig, SNAC
Dr Desmond Yip, AGITG
Professor John Zalcberg, AGITG
Staff activities
SUPERVISION OF RESEARCH DEGREES
John Simes
Jordan Fulcher: PhD
Chee Lee: PhD
Rachel O’Connell: PhD
Manjula Schou: PhD
Lukas Staub: PhD
Anthony Keech
Jordan Fulcher: PhD
Jason Harmer: PhD
Kushwin Rajamani: PhD
Ru-Dee Ting: PhD
Lisa Askie
Angela Carberry: PhD
Filip Cools: PhD
Val Gebski
Mithilesh Dronavalli: MMedSc
Annette Kifley: PhD
Chee Lee: PhD
Zhixin Liu: PhD
Farnoush Noushi PhD
Bee Choo Tai: PhD
Malcolm Hudson
Rachel O’Connell: PhD
Prunella Blinman: PhD
Sally Lord
Chee Lee: PhD
Lukas Staub: PhD
Deborah Schofield
Emily Callander: PhD
Hannah Verry: PhD
Rupendra Shrestha
Emily Callander: PhD
Hannah Verry: PhD
Martin Stockler
Prunella Blinman: PhD
Lesley Shan Wu Chim: PhD
Haryana Dhillon: PhD
Belinda Kiely: PhD
Philippa Marks: MClinEpi
Michaella Smith: PhD
EXTERNAL COMMITTEES
John Simes
ANZ Breast Cancer Trials Group scientific 
advisory committee
Aspirin to Prevent Recurrent Venous 
Thrombo-embolism (ASPIRE) trial 
management committee (chair)
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee, 
operations executive committee, MAX trial 
management committee, Quasar 2 trial 
management committee, Da Vinci trial 
management committee
Australian New Zealand Clinical Trials 
Registry (ANZCTR) policy advisory 
committee
Cancer Clinical Trials Development Unit 
(CTDU) advisory committee, management 
committee and health economics advisory 
committee
Cancer Institute NSW board
Cholesterol Treatment Trialists Collaboration 
(CTTC) (joint coordinator)
Cochrane Collaboration prospective meta-
analysis methods working group
Cooperative Trials Group for Neuro-
Oncology (COGNO) scientific advisory 
committee (deputy chair)
Benefits of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee, executive, and cost-
effectiveness subcommittee
Intensive Blood Pressure Reduction 
for Acute Cerebral Haemorrhage Trial 
(INTERACT) safety and data monitoring 
committee (chair)
International Breast Cancer Intervention 
Study (IBIS-II) international steering 
committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-Embolism 
(INSPIRE) steering committee (chair)
Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee, executive, samples 
subcommittee
National Health and Medical Research 
Council large-scale clinical trials committee 
(chair)
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
Percutaneous Coronary Angioplasty versus 
Thrombolysis (PCAT) collaborative group 
(co-coordinator)
Polypill trials safety and data monitoring 
committee (chair)
Sentinel Biopsy versus Axillary Clearance 
(SNAC) trial management committee
Trials associate editor
Virtual Coordinating Centre for International 
Collaborative Cardiovascular Research 
(VIGOUR) statistical group (chair) and a 
VIGOUR leader
Anthony Keech
Asian-Pacific Society of Atherosclerosis 
and Vascular Disease Prevention executive 
committee (APSAVD) (founding member 
and treasurer)
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Asia-Pacific Study on CHD Risk Factor 
Intervention (ASPAC) management 
committee (principal investigator and study 
chairman)
BLISS study safety and data monitoring 
committee (chairman)
Cardiac Society of Australia and New 
Zealand clinical trials working group 
scientific committee (chairman)
Cholesterol Treatment Trialists’ 
Collaboration (CTTC) (joint coordinator and 
convenor)
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee (principal investigator and 
study chairman), ophthalmology substudy 
committee, scientific substudies committee, 
cost-effectiveness substudies committee
Heart Protection Study (HPS) steering 
committee, executive committee (co-
principal investigator)
International Journal of Cardiology clinical 
trials editor
ISIS Trials Group steering committee
Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) study 
management committee, executive, and 
quality assurance subcommittee
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
National Health and Medical Research 
Council training awards committee
NSW Department of Health shared 
assessment committee
PLoS Medicine editorial board
Prospective Pravastatin Pooling (PPP) 
project international steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
University of Sydney College of Health 
Sciences board of postgraduate studies
University of Sydney Faculty of Medicine 
budget advisory committee and faculty 
awards committee, Department of Public 
Health research committee
Virtual Coordinating Centre for International 
Collaborative Cardiovascular Research 
(VIGOUR)
Lisa Askie
Antenatal Magnesium IPD International 
Collaboration (AMICABLE) individual 
patient data collaboration steering 
committee
Antenatal Magnesium Sulphate prior to 
Preterm Birth for Neuroprotection of the 
Fetus infant and child national clinical 
practice guidelines, executive panel
Benefits of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Cochrane Collaboration prospective 
meta-analysis methods working group (co-
convenor) and methods editorial board
Early Prevention of Childhood Obesity 
(EPOCH) prospective meta-analysis 
collaboration steering committee (chair)
International Clinical Trials Registry 
Platform, World Health Organization, best 
practice group
International Forum for Standards for 
Research in Children sample size and 
data safety monitoring committee 
subcommittee
Meta-Analysis of Preterm Patients 
on Inhaled Nitric Oxide (MAPPINO) 
Collaboration steering group
Neonatal Oxygen Prospective Meta-
analysis (NeOProM) collaboration steering 
committee (chair)
Perinatal Antiplatelet Review of 
International Studies (PARIS) collaboration 
steering committee, writing committee 
(chair)
PLoS ONE academic editor
Prenatal Repeat Corticosteroid International 
IPD Study Group: Assessing the Effects 
Using the Best Level of Evidence (PRECISE) 
steering committee
Prevention of Ventilation Induced Lung 
Injury Collaborative Group (PREVILIG) 
steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Amy Boland
Australian & New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP) 
operations executive committee, scientific 
advisory committee, and Accelerated BEP, 
Aprepitant for Germ Cell Chemotherapy, 
Chemo & Cognition, SORCE and EVERSUN 
trial management committees
Mark Chatfield
Accelerated BEP trial management 
committee
Aprepitant trial management committee
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee
Jenny Chow
Cancer Institute NSW Neuro-oncology 
Group (NSWOG), COGNO operations 
executive, management committee, COSA 
executive officers network
Christopher Brown
Cooperative Trials Group for Neuro-
Oncology (COGNO) scientific advisory 
committee, operational executive 
committee; CABARET trial management 
committee
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee, 
operational executive committee; NITRO 
trial management committee, B2P2M2 trial 
management committee
Xanthi Coskinas
Australasian Lung cancer Trials Group 
(ALTG) scientific advisory committee, 
operational executive committee; NITRO 
trial management committee, B2P2M2 trial 
management committee, PACT in NSCLC 
trial management committee
Trevor France
Co-operative Trials Group for Neuro-
Oncology (COGNO) operations executive 
and scientific advisory committees, and 
CABARET and CATNON trial management 
committees
Val Gebski
Adjuvant chemotherapy versus surgery 
alone in patients with stage II AND IIIB 
gastric adenocarcinoma safety and data 
monitoring committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee and 
MAX, Da Vinci, ATTAX, ATTAX2, DECO, ABC, 
Gofurtgo, TOPGEAR, ATTACHE, ATTAX3 
trial management committees
Australasian KidneyTrials Network advisory 
board
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and TRIPOD, Symptom 
Benefit, and Outback trial management 
committees
Australian & New Zealand Urinary and 
Prostate Trials Group (ANZUP) scientific 
advisory committee and Accelerated BEP 
and Eversun trial management committees
Australian New Zealand Breast Cancer 
Trials Group (ANZ BCTG) scientific advisory 
committee and LATER,  NeoGem and 
ANZ001 trial management committees
Avastin use in platinum-resistant epithelial 
ovarian cancer safety and data monitoring 
committee
Biostatistics Collaboration of Australia 
steering committee and teaching 
committee
GCIG/GINECO GCIG intergroup study 
comparing pegylated liposomal doxorubicin 
(Caelyx) and carboplatin versus paclitaxel 
and carboplatin in patients with epithelial 
ovarian cancer trial management committee
LACC trial management committee
LACE trial management committee
Medical Journal of Australia consultant 
statistician
Multicentre study of RAD in the treatment 
of pulmonary fibrosis safety and data 
monitoring committee
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NMRC Singapore Indomethacin study for 
closure of PDA safety data and monitoring 
committee
NSW Health Eastern Sydney Area ethics 
committee clinical trials subcommittee
Oxygen versus air in oxygen-naïve patients 
with refractory dyspnoea and PaO2>55 
safety and data monitoring committee
SNAC trial management committee
Testosterone undecanoate in obese men as 
adjuvant therapy for a weight loss program 
safety and data monitoring committee
Trastuzumab with a fluoropyrimidine and 
cisplatin versus chemotherapy alone as first-
line therapy in patients with HER2 positive 
advanced gastric cancer safety and data 
monitoring committee
Westmead Cancer Care Joint Radiation 
Oncology Centre research committee
Reena Gill
Australasian Gastro-Intestinal Trials Group 
(AGITG), operations executive committee, 
and PETACC-6, SURGIST and REGISTER and 
CO.20 trial management committees
Wendy Hague
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
Benefits of Oxygen Saturation Targeting 
(BOOST II) management committee
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
Australian Placental Transfusion Study 
(APTS) management committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) trials operations committee
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) trials 
operations committee
Cancer Institute NSW infrastructure grant 
steering committee and human research 
ethics committee
Adrienne Kirby
Australian Placental Transfusion Study 
(APTS) management committee
Benefits of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Erica Jobling
Biostatistics Collaboration of Australia 
writing group
National Curriculum for Entomology 
evaluation committee
Ann Livingstone
Co-operative Trials Group for Neuro-
Oncology (COGNO) operations executive 
and scientific advisory committees
Julie Martyn
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee, operations executive 
committee and study coordinators 
committee
Cancer Institute NSW infrastructure grant 
subcommittee
Gynecological Cancer Intergroup (GCIG) 
harmonisation and statistics committee 
(chair)
iCON-7, PORTEC-3 and OVAR-16 
international steering committees
TRIPOD, Symptom Benefit, PORTEC-3 and 
Outback trial management committees
Danielle Miller
Cancer Australia Clinical Trials Development 
Unit (CTDU) program management 
committee, strategic advisory committee 
and health economics subcommittee
Primary Care Collaborative Cancer Clinical 
Trials Group (PC4) operations team and 
scientific advisory committee
SNAC 1 and SNAC 2 trial management 
committees
Australasian Gastro-Intestinal Trials Group 
(AGITG) TOPGEAR trial management 
committee
Rebecca Mister
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
Rhana Pike
Australasian Medical Writers Association 
executive committee (vice-president)
Deborah Schofield
International Medical Workforce planning 
committee
School of Public Health research committee, 
Faculty of Medicine, University of Sydney
Katrin Sjoquist
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and operations 
executive committee, Symptom Benefit 
trial management committee, Australasian 
Gastro-Intestinal Trials Group (AGITG) 
scientific advisory committee and 
operations executive committee, ATTACHE 
trial management committee, PAN1 CTC 
clinical lead
Martin Stockler
Australasian Leukaemia & Lymphoma Group 
safety and data monitoring committee
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop 
steering committee (co-convenor)
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee
Australian and New Zealand Breast Cancer 
Trials Group (ANZ BCTG) scientific advisory 
committee
Cancer Council Australia national oncology 
education committee
Cancer Trials NSW steering committee, trial 
selection committee (chair), centre selection 
committee
Cochrane Collaboration advanced breast 
cancer working party
Journal of Clinical Oncology editorial board
National Breast Cancer Centre eClinical 
Updates editorial board
National Breast Cancer Centre clinical 
updates advisory committee
National Breast Cancer Centre hormone 
therapy working group (chair) and 
information advisory group (chair)
National Breast Cancer Foundation Strategic 
research advisory panel
National Cancer Institute (NCI) Intergroup 
health related quality-of-life committee
National Health and Medical Research 
Council grant review panels for oncology 
and palliative care strategic grants
University of Sydney Faculty of Medicine 
oncology block committee (chair), EBM 
in GMP3/4 (chair), evidence-based 
medicine resource group, integrated clinical 
attachment committee and usmp cancer 
planning committee
Burcu Vachan
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive, biological 
subcommittee
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee, operations 
executive and executive
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) operations 
executive and research advisory committee
Australasian Lung Cancer Trials Group 
(ALTG) operations executive and scientific 
advisory committee
Australian New Zealand Breast Cancer Trials 
Group (ANZ BCTG)
Cancer Institute NSW infrastructure grant 
subcommittee
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Cancer Institute NSW partnership grant 
operational executive committee
Kate Wilson
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee, study 
coordinators subcommittee (chair), annual 
scientific meeting committee, and MAX, 
Quasar 2, ATTAX, DECO, and A La CaRT and 
SUPER trial management committees
Cancer Institute NSW infrastructure grant 
subcommittee
Nicole Wong
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee 
and ATTACHE, LAP07, SCOT and ATTAX 3 
trial management committees
Sonia Yip
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive and biological 
subcommittee
Australian and New Zealand Urogenital and 
Prostate Group (ANZUP) scientific advisory 
committee, renal cell subcommittee, germ 
cell subcommittee, and EVERSUN and 
SORCE trial management committees
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee and 
B2P2M2 trial management committee
Cooperative Trials Group for Neuro-
Oncology (COGNO) scientific advisory 
committee.
ACADEMIC TEACHING
John Simes
Decision analysis, Master of Public Health 
and Master of Medicine, University of 
Sydney
Anthony Keech
Cardiology training, and clinical tutor, Royal 
Prince Alfred Hospital
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University of 
Sydney (convener)
University of Sydney Graduate Medical 
Program
Lisa Askie
Advanced clinical data management, 
Master of Health Information Management, 
University of Sydney
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney 
(co-coordinator)
Controlled clinical trials, Master of Public 
Health, University of Sydney
Evidence-based medicine in the clinical 
years, University of Sydney Medical Program
Elizabeth Barnes
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Principles of statistical inference, 
Biostatistics Collaboration of Australia
Prunella Blinman
Oncology and palliative care, University of 
Sydney Medical Program
Christopher Brown
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Mark Chatfield
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Val Gebski
Advanced clinical trials, Biostatistics 
Collaboration of Australia (coordinator)
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Radiation oncology training, RACR trainees, 
Westmead Hospital, NSW Cancer Council
Adrienne Kirby
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Sally Lord
Advanced evaluation of diagnostic tests, 
and Decision analysis, Master of Public 
Health and Master of Medicine, University 
of Sydney
Critical appraisal, Basic sciences in oncology, 
NSW Cancer Council
Evidence-based medicine, University of 
Sydney Medical Program
Andrew Martin
Decision analysis, and Controlled clinical 
trials, Master of Public Health and Master of 
Medicine, University of Sydney
Rebecca Mister
Advanced clinical data management, 
Master of Health Information Management, 
University of Sydney
Rachel O’Connell
Principles of statistical inference, 
Biostatistics Collaboration of Australia
Deborah Schofield
Health workforce policy analysis, School of 
Public Health, University of Sydney
Katrin Sjoquist
Evidence-based medicine in the clinical 
years, University of Sydney Medical Program
Lukas Staub
Screening and diagnostic test evaluation, 
Master of Public Health and Master of 
Medicine, University of Sydney
Martin Stockler
Australia & Asia-Pacific Clinical Oncology 
Research Development (ACORD) convenor, 
and international steering committee 
(chair)
Making sense of cancer clinical trials for 
NSW medical oncology trainees (convenor)
Clinical epidemiology for physician trainees, 
Royal Prince Alfred Hospital
Evidence-based medicine in the clinical 
years, (chair and coordinator), and Oncology 
and palliative care  (block chair), University 
of Sydney Medical Program
Medical oncology clinical training, Royal 
Prince Alfred Hospital
Patient-based measures, Master of 
Medicine, University of Sydney (course 
coordinator)
Quality of life in oncology, Cancer Institute 
NSW
Sonia Yip
Evidence-based medicine, and Oncology 
problem-based learning, University of 
Sydney Medical Program
Diana Zannino
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Basic sciences in oncology, NSW Cancer 
Council
Publications
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